These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 862650)

  • 1. Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance.
    Zilly W; Breimer DD; Richter E
    Eur J Clin Pharmacol; 1977 Apr; 11(4):287-93. PubMed ID: 862650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.
    Zilly W; Breimer DD; Richter E
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):219-27. PubMed ID: 1233266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents.
    Richter E; Breimer DD; Zilly W
    Eur J Clin Pharmacol; 1980; 17(3):197-202. PubMed ID: 7363932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine.
    Breimer DD; Zilly W; Richter E
    Clin Pharmacol Ther; 1977 Apr; 21(4):470-81. PubMed ID: 849678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the pig.
    van den Broek JM; Teunissen MW; Breimer DD
    Drug Metab Dispos; 1981; 9(6):541-4. PubMed ID: 6120813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of corticosteroid on hexobarbital and tolbutamide disposition.
    Breimer DD; Zilly W; Richter E
    Clin Pharmacol Ther; 1978 Aug; 24(2):208-12. PubMed ID: 679598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic interactions with rifampicin.
    Zilly W; Breimer DD; Richter E
    Clin Pharmacokinet; 1977; 2(1):61-70. PubMed ID: 140033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of rifampicin on the metabolic clearance of galactose and antipyrine as compared with hexobarbital].
    Zilly W; Wernze H; Buchenau D; Breimer DD; Richter E
    Verh Dtsch Ges Inn Med; 1975; 81():1677-80. PubMed ID: 1227056
    [No Abstract]   [Full Text] [Related]  

  • 9. Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin.
    Smith DA; Chandler MH; Shedlofsky SI; Wedlund PJ; Blouin RA
    Br J Clin Pharmacol; 1991 Dec; 32(6):735-9. PubMed ID: 1768567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery.
    Breimer DD; Zilly W; Richter E
    Clin Pharmacol Ther; 1975 Oct; 18(4):433-40. PubMed ID: 1164825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbtamide in man.
    Svendsen TL; Kristensen MB; Hansen JM; Skovsted L
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):439-41. PubMed ID: 971708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of diethyldithiocarbamate on the metabolic elimination of hexobarbital, phenazone, tolbutamide and four halogenated hydrocarbons.
    Siegers CP; Biltz H; Pentz R
    Eur J Drug Metab Pharmacokinet; 1981; 6(2):141-8. PubMed ID: 6268415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug clearance as a decision aid for further invasive liver diagnosis--studies with hexobarbital as a model substrate].
    Zilly W; Richter E
    Z Gastroenterol; 1992 May; 30(5):325-8. PubMed ID: 1385917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter: Rifampicin and drug metabolism.
    Syvälahti EK; Pihlajamäki KK; Iisalo EJ
    Lancet; 1974 Jul; 2(7874):232-3. PubMed ID: 4135664
    [No Abstract]   [Full Text] [Related]  

  • 15. [Metabolism of hexobarbital in patients with acute hepatitis and cirrhosis (author's transl)].
    Richter E; Gallenkamp H; Keller B; Brachtel D; Zilly W; Breimer DD
    Z Gastroenterol; 1977 Jun; 15(6):381-8. PubMed ID: 888488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of drug metabolism during cholestasis in man.
    Carulli N; Manenti F; Ponz de Leon M; Ferrari A; Salvioli G; Gallo M
    Eur J Clin Invest; 1975 Nov; 5(6):455-62. PubMed ID: 1201763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of hexobarbital and dipyrone in critical care patients receiving high-dose pentobarbital.
    Heinemeyer G; Gramm HJ; Simgen W; Dennhardt R; Roots I
    Eur J Clin Pharmacol; 1987; 32(3):273-7. PubMed ID: 3595700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide.
    Williams RL; Blaschke TF; Meffin PJ; Melmon KL; Rowland M
    Clin Pharmacol Ther; 1977 Mar; 21(3):301-9. PubMed ID: 837649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of hexobarbital in the rat. Estimation of "first-pass" elimination and influence of ether anesthesia.
    Vermeulen NP; Danhof M; Setiawan I; Breimer DD
    J Pharmacol Exp Ther; 1983 Jul; 226(1):201-5. PubMed ID: 6864540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of propranolol metabolism by rifampicin.
    Herman RJ; Nakamura K; Wilkinson GR; Wood AJ
    Br J Clin Pharmacol; 1983 Nov; 16(5):565-9. PubMed ID: 6639842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.